Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Focal Segmental Glomerulosclerosis Drugs Market Size, Value And Growth Trajectory Through 2030
The focal segmental glomerulosclerosis drugs market size has demonstrated robust growth in recent years. It is anticipated to increase from $17 billion in 2025 to $18.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. This historical expansion can be ascribed to several factors, including limited available treatment options, the high prevalence of kidney diseases, a reliance on corticosteroids, growing awareness of FSGS, and progress in immunosuppressive drugs.
The focal segmental glomerulosclerosis drugs market is anticipated to experience significant expansion in the coming years. This market is projected to reach $27.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. The projected growth during this period is largely driven by factors such as the increasing use of biologics and monoclonal antibodies, the emergence of personalized medicine strategies, greater financial support for rare disease research, the incorporation of technology into treatment development, and the improvement of healthcare facilities in developing regions. Key trends expected over the forecast horizon include advancements in personalized medicine, focused research on targeted therapeutics, the broadening of the rare disease drug pipeline, enhanced efficiency in clinical trials, and improvements in immunomodulatory therapies.
Get A Free Sample Report With In-Depth Market Insights:
Focal Segmental Glomerulosclerosis Drugs Market Growth Momentum: What Factors Are Shaping Demand?
The growth of the focal segmental glomerulosclerosis (FSGS) drugs market is anticipated to be propelled by increasing healthcare expenditure in the future. Healthcare expenditure refers to the total amount of money spent on healthcare services and related goods and activities within a specific healthcare system or economy over a defined period. Elevated healthcare spending can significantly aid the development and availability of drugs for focal segmental glomerulosclerosis (FSGS), as it boosts research funding and clinical trials, thereby enhancing drug output. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based Institute for Health Information, total health spending in Canada is projected to reach $344 billion in 2023, which equates to $8,740 per person. This figure signifies a 2.8% increase compared to the previous year, where health spending saw only a 1.5% growth in 2022, indicating a notable rebound in healthcare investment. Therefore, rising healthcare expenditures are a key driver for the expansion of the focal segmental glomerulosclerosis (FSGS) drugs market.
Focal Segmental Glomerulosclerosis Drugs Market Segment Performance And Emerging Opportunities
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Focal Segmental Glomerulosclerosis Drugs Market Trends Redefining Industry Growth
Major companies engaged in the focal segmental glomerulosclerosis (FSGS) market are increasingly prioritizing product development and innovation to deliver reliable products to their customers and strengthen their market standing. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI for focal segmental glomerulosclerosis (FSGS), which received approval from the Food and Drug Administration (FDA), a US-based federal agency. This oral medicine is used for treating IgA nephropathy (IgAN). It stands as the first and only non-immunosuppressive treatment available for lowering proteinuria in IgAN, a rare kidney disease. Furthermore, FILSPARI has been granted orphan drug designation in the United States and Europe for the treatment of both IgAN and focal segmental glomerulosclerosis (FSGS).
Focal Segmental Glomerulosclerosis Drugs Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio, Alexion Pharmaceuticals, Bayer AG, Novartis AG, Pfizer Inc., Johnson and Johnson Ltd., Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Fresenius Kabi Ltd., Gilead Sciences Inc, Reata Pharmaceuticals, Amgen Inc
View The Full Focal Segmental Glomerulosclerosis Drugs Market Report:
Focal Segmental Glomerulosclerosis Drugs Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2025. The regions covered in the focal segmental glomerulosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
